Evidence map›Paper›PMID 31387590›Full record

ReviewJournal of biomedical science2019

Atherosclerosis and flow: roles of epigenetic modulation in vascular endothelium.

Ding-Yu Lee, Jeng-Jiann Chiu

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of biomedical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Atherosclerosis plus · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Pulsatile flow induces chromatin interaction with lamin-associated proteins to enrich H3K9 methylation in endothelial cells.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Symmetry and asymmetry in atherosclerosis.International journal of occupational medicine and environmental health · 2023
    Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ding-Yu LeeDepartment of Biological Science and Technology, China University of Science and Technology, Taipei, 115, Taiwan.
Jeng-Jiann ChiuInstitute of Cellular and System Medicine, National Health Research Institutes, Miaoli, 350, Taiwan. jjchiu@nhri.org.tw.ORCID http://orcid.org/0000-0003-4071-7367
China University of Science and Technology · TWNational Health Research Institutes · TW

Funding

Ministry of Science and Technology, Taiwan MOST-107-2320-B-157-001Ministry of Science and Technology, Taiwan MOST-107-2321-B-400-001Ministry of Science and Technology, Taiwan MOST-108-2320-B-157-001Ministry of Science and Technology, Taiwan MOST-108-2633-B-009-001National Health Research Institutes, and Central Government S & T grants, Taiwan 108-1901-01-19-08/108-1901-01-19-07/107-1901-01-19-03/ MOST106-3114-Y-043-021/108-0324-01-19-07/107-0324-01-19-03/106-0324-01-10-07/105-0324-01-10-03
6 · The paper itself

Abstract

backgroundEndothelial cell (EC) dysfunctions, including turnover enrichment, gap junction disruption, inflammation, and oxidation, play vital roles in the initiation of vascular disorders and atherosclerosis. Hemodynamic forces, i.e., atherprotective pulsatile (PS) and pro-atherogenic oscillatory shear stress (OS), can activate mechanotransduction to modulate EC function and dysfunction. This review summarizes current studies aiming to elucidate the roles of epigenetic factors, i.e., histone deacetylases (HDACs), non-coding RNAs, and DNA methyltransferases (DNMTs), in mechanotransduction to modulate hemodynamics-regulated EC function and dysfunction. OS enhances the expression and nuclear accumulation of class I and class II HDACs to induce EC dysfunction, i.e., proliferation, oxidation, and inflammation, whereas PS induces phosphorylation-dependent nuclear export of class II HDACs to inhibit EC dysfunction. PS induces overexpression of the class III HDAC Sirt1 to enhance nitric oxide (NO) production and prevent EC dysfunction. In addition, hemodynamic forces modulate the expression and acetylation of transcription factors, i.e., retinoic acid receptor α and krüppel-like factor-2, to transcriptionally regulate the expression of microRNAs (miRs). OS-modulated miRs, which stimulate proliferative, pro-inflammatory, and oxidative signaling, promote EC dysfunction, whereas PS-regulated miRs, which induce anti-proliferative, anti-inflammatory, and anti-oxidative signaling, inhibit EC dysfunction. PS also modulates the expression of long non-coding RNAs to influence EC function. i.e., turnover, aligmant, and migration. On the other hand, OS enhances the expression of DNMT-1 and -3a to induce EC dysfunction, i.e., proliferation, inflammation, and NO repression.

conclusionOverall, epigenetic factors play vital roles in modulating hemodynamic-directed EC dysfunction and vascular disorders, i.e., atherosclerosis. Understanding the detailed mechanisms through which epigenetic factors regulate hemodynamics-directed EC dysfunction and vascular disorders can help us to elucidate the pathogenic mechanisms of atherosclerosis and develop potential therapeutic strategies for atherosclerosis treatment.

Indexed as

Epigenesis, GeneticAnimalsAtherosclerosisDNA MethylationEndothelial CellsHemodynamicsHistone DeacetylasesHumansMechanotransduction, CellularRNA, UntranslatedHistone DeacetylasesRNA, UntranslatedDNA methyltransferaseEndothelial cellEpigenetic factorHemodynamic forceHistone deacetylaseNon-coding RNA

Identifiers

PMID31387590
PMCPMC6685237
OpenAlexW2964584906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.